UAE Marketing Regulation

Healthcare regulations safeguard public health by ensuring accurate information and ethical marketing. They prevent misleading claims, promote responsible advertising, and require scientific evidence for product claims. This empowers patients with reliable information and protects them from misuse of medications. Regulations also ensure fair competition within the industry.
Federal Law No. 8 of 2019 on Medical Products, Profession of Pharmacy and Pharmaceutical Institutions (the “2019 Law”) supersedes Law No. 4 of 1983 and Law No. 20 of 1995. It provides a comprehensive framework regulating medical products in the UAE, including pharmaceuticals, medical devices, and healthcare products.
The law governs import, export, distribution, warehousing, manufacturing, pricing, registration, advertising, promotion, clinical trials, safety reporting, and product recalls. It sets strict conditions for advertising medical products, with violations constituting criminal offenses punishable by fines or imprisonment.
The Ministry of Health and Prevention (MOHAP) is the primary regulator governing advertising of medical products. Certain Emirates have additional authorities such as the Dubai Health Authority (DHA), Health Authority Abu Dhabi (HAAD), and Sharjah Health Authority (SHA), which enforce local regulations.
Market Authorisation from MOHAP is mandatory before any medical product may be imported, distributed, or advertised. Authorisation is granted only after registration and classification of the product by MOHAP.
Advertising approval applications are submitted online through MOHAP, typically by a UAE-based marketing agent. Applications must include the Marketing Authorisation, advertisement samples, and details of media platform, location, and duration.
In some cases, additional approvals from DHA, HAAD, or SHA may be required. Advertisement fees vary by category and medium in accordance with Cabinet Resolution No. 7/2007.
Article 39 prohibits advertising prescription-only medicines, except in scientific publications intended for healthcare professionals and only with MOHAP approval.
Advertising of non-prescription medicines and non-prescription medical devices is permitted, provided the product has Marketing Authorisation and the advertisement is approved by MOHAP.
Advertisements must be accurate, balanced, impartial, and non-misleading. They must allow recipients to form independent opinions and include information on contraindications, precautions, and side effects. Terms such as “safe” and “effective” must be used cautiously.
Prior consent from healthcare professionals is required before marketing via email, SMS, or other electronic communications.
Strict controls govern hospitality and gifts offered to healthcare professionals by medical product companies or during sponsored events.
Additional restrictions apply to sponsorship of conferences, education programs, and similar activities.
Requirements mirror those for healthcare professionals, with mandatory MOHAP approval prior to publication across all media.
All promotional data must be accurate, balanced, and approved by MOHAP. Advertising must not mislead through distortion, exaggeration, omission, or undue emphasis.
Conflicting scientific studies must be disclosed. Animal study data must not be cited if it may misrepresent relevance to humans.
Comparative advertising must be based on relevant and comparable criteria, must not mislead or denigrate competing products, and must be scientifically valid.
False or misleading comparisons constitute unfair competition under Federal Commercial Transactions Law No. 18 of 1993 and Consumer Protection Law No. 15 of 2020.
All online and social media advertising must be reviewed and approved by MOHAP before publication.
EMR requires prior approval and a UAE Media Council license for online advertising, including influencer marketing involving paid or non-monetary benefits.
Advertisements on digital platforms must include clear disclosure that the content is advertising.
These guidelines require transparency in promotional relationships and prohibit promotion of non-therapeutic, unproven, or harmful products.
Regulatory clarification is ongoing regarding whether displaying medical products on e-commerce platforms constitutes advertising, particularly in relation to e-pharmacies.
MOHAP is the primary regulator overseeing advertising and promotion of medical products.
Join hundreds of companies who trust OMC Medical for their regulatory needs.